Endothelial progenitor cells (EPCs) have a critical role in angiogenesis and vasculogenesis of coronary artery disease (CAD) patients. Secretome of human Umbilical Cord Blood-Mesenchymal Stem Cell (hUCB-MSCs) can promote neovascularization. Ramiprilat is an active metabolite of ramipril that has shown benefit in cardiovascular disease. The effect of hUCB-MSCs-derived secretome alone or combination with ramiprilat on EPCs migration is not yet elucidated. This study aimed to identify the effect of hUCB- MSC derived secretome and its combination with ramiprilat on EPCs migration. EPCs were collected from peripheral blood of CAD patient and cultured in the Stemline II medium. Cultured EPCs were then divided into groups of control, ramiprilat 10 μmol, hUCB-MSCs derived secretome (2%, 10%, and 20%), and its combination. The migration of EPCs was assessed using a Boyden chamber assay. Ramiprilat and hUCB-MSCs-derived secretome at all doses increase EPCs migration in dose-dependent manner. Combination of hUCB-MSCs-derived secretome at dose 10% and 20% and ramiprilat significantly increase migrated cells compared to ramiprilat only and secretome only group (p<0.001). In conclusion, hUCB-MSCs-derived secretome and ramiprilat enhance EPCs migration and combination of those two substances furtherly increased the migrated cells. hUCB-MSCs-derived secretome has the potential as regenerative treatment for CAD patients.